← Back to Clinical Trials
Recruiting NCT06472999

NCT06472999 Nephroprotective Measures in Critically Ill Patients With Moderate/Severe Acute Kidney Injury

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06472999
Status Recruiting
Phase
Sponsor Universität Münster
Condition Acute Kidney Injury
Study Type OBSERVATIONAL
Enrollment 257 participants
Start Date 2024-07-24
Primary Completion 2025-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Nephroprotective measures

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 257 participants in total. It began in 2024-07-24 with a primary completion date of 2025-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study investigates to which extent recommended nephroprotective measures are implemented in critically ill patients with moderate or severe acute kidney injury.

Eligibility Criteria

Inclusion Criteria: 1. Critically ill patients with moderate or severe AKI (KDIGO stage 2 / 3) 2. Requirement of vasopressors or mechanical ventilation 3. Age ≥ 18 years 4. Informed consent Exclusion Criteria: 1. Chronic kidney disease (CKD) with a glomerular filtration rate \< 20ml/min 2. Chronic dialysis dependency 3. History of renal transplantation 4. Permanent ligation of the renal arteries 5. AKI immediately following nephrectomy 6. Patients requiring permanent administration of nephrotoxic drugs (e.g. immunosuppressive therapy afer liver transplantation) 7. Persons with any kind of dependency on the investigator or employed by the sponsor or investigator.

Contact & Investigator

Central Contact

Melanie Meersch-Dini, MD

✉ meersch@uni-muenster.de

📞 +492518347255

Principal Investigator

Alexander Zarbock, MD

PRINCIPAL INVESTIGATOR

University Münster

Frequently Asked Questions

Who can join the NCT06472999 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06472999 currently recruiting?

Yes, NCT06472999 is actively recruiting participants. Contact the research team at meersch@uni-muenster.de for enrollment information.

Where is the NCT06472999 trial being conducted?

This trial is being conducted at Innsbruck, Austria, Münster, Germany, Nijmegen, Netherlands.

Who is sponsoring the NCT06472999 clinical trial?

NCT06472999 is sponsored by Universität Münster. The principal investigator is Alexander Zarbock, MD at University Münster. The trial plans to enroll 257 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology